Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5QO1A)

• Drug Name: LY3415244 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM5QO1A

Molecule-Related Drug Atlas

Drug(s) Targeting Hepatitis A virus cellular receptor 2 (TIM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MBG453	DMBPY9Z	Myelodysplastic syndrome	2A37	Phase 3	[3]
RO7121661	DM8A120	Esophageal squamous cell carcinoma	2E60.1	Phase 2	[4]
GSK4069889	DMV6SNU	Non-small-cell lung cancer	2C25	Phase 2	[5]
AZD7789	DMOIHWI	Hodgkin lymphoma	2B30	Phase 2	[6]
TB006	DMKN524	Alzheimer disease	8A20	Phase 2	[7]
BGB-A425	DMI42Q0	Non-small-cell lung cancer	2C25	Phase 1/2	[8]
LY3321367	DMD51GC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
Sym023	DMV3L62	Lymphoma	2A80-2A86	Phase 1	[9]
INCAGN2390	DM5SO1T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[11]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[12]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[13]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[14]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[15]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[16]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[19]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis A virus cellular receptor 2 (TIM3)	TT1RWL7	HAVR2_HUMAN	Inhibitor	[2]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03752177) A Study of LY3415244 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [6] Clinical pipeline report, company report or official report of AstraZeneca
• [7] Clinical pipeline report, company report or official report of TrueBinding
• [8] Clinical pipeline report, company report or official report of BeiGene.
• [9] Clinical pipeline report, company report or official report of Symphogen.
• [10] Clinical pipeline report, company report or official report of Agenus.
• [11] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [14] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [17] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [18] National Cancer Institute Drug Dictionary (drug id 740856).
• [19] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [20] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.